Draft:Equashield
| Submission declined on 6 October 2023 by Voorts (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: To the reviewer: This article comply with the specific notability guideline for organizations and companies (WP:COMPANY): 1) WP:ORGIN: This company has attracted the notice of reliable sources unrelated to the organization or product
2) WP:ORGCRIT This company is notable because it has been the subject of significant (WP:ORGDEPTH) coverage in multiple reliable secondary sources that are independent of the subject (WP:ORGIND).
3) The company sold 25% stake to Nordic Capital at $1.3 billion valuation.
There is no PROMOTION in this article.
Thenks - Ovedc (talk) 14:45, 19 July 2023 (UTC)
 | |
 | |
| Company type | company |
|---|---|
| Industry | Closed system drug transfer device industry |
| Founded | 2009 |
| Headquarters | New York City |
Key people | Eric Shem-Tov, CEO |
| Products |
|
| Website | https://www.equashield.com/ |
Equashield is a global privately held medical device company. It is focused on protecting healthcare workers from hazardous drug exposure by developing automated compounding robots and Closed system drug transfer devices.[1][2] Its products are sold in over 25 countries across 5 continents and are the most used CSTD in the United States.[3][4][5]
History
[edit]Equashield was founded by Eric Shem-Tov and Marino Kriheli in 2009.[6]
The company was established with the aim of developing a new generation of closed-system drug transfer devices (CSTDs) to address the safety concerns associated with handling hazardous drugs in healthcare settings.
Equashield Opened $30 Million Manufacturing Facility in 2019.[7]
in 2020, Equashield sold 25% stake to Nordic Capital at $1.3 billion valuation.[4]
Products
[edit]EQUASHIELD CSTD
[edit]
The fully encapsulated Syringe Units prevents the exposure to syringe plunger and barrel contamination caused by hazardous drug handling.[8]
Syringe Units
[edit]The system is equipped with a built-in closed pressure equalization with sterile air. The connector is permanently bonded onto the syringe body preventing accidental disconnections and house shielded needles to prevent the risk of accidental needle sticks.[9]
Vial adaptors
[edit]Vial Adaptor firmly snaps onto a standard vial with a unique mechanism that prevents angled or non-centered spiking. The vial adaptor provides a safe and contamination-free vial access port for the Syringe Unit.
The vial adaptor’s elastomeric membrane serves a dual purpose; to serve as a microbial barrier preventing microbial ingress, remaining drug residue-free for up to 10 repeated connections in 7 days.[10]
Spike adaptors
[edit]Spike adaptors are designed to firmly connect between any standard IV bag and tubing set, enabling the safe transfer of medication dose into the IV Bag. Considering variations among various IV Bag manufacturers
The SA-W is designed for safe and cost-effective withdrawal of diluent for reconstitution with the Syringe Units (SU). Designed also to work in conjunction with FC-180 to cost-effectively administer multiple consecutive medications to a patient while maintaining a closed system.[11]
EQUASHIELD PRO
[edit]
EQUASHIELD® Pro is an automated compounding robot. Utilizing CSTD.
Unlike traditional robot’s reliance on robotic arms that mimic human motion with the use of conventional needle and syringe methods, which may potentially lead to cytotoxic drips, spills, aerosols and vapor release, EQUASHIELD Pro uses a multi-station compounding approach to minimize both the motion and time it takes to prepare a dose, much like a factory manufacturing line.[12]
EQUASHIELD® Pro is designed to make the adoption of robotics simple and affordable in the IV compounding workspace. It is comparable in size to a standard Biological Safety Cabinet, making it easy to fit into hospital pharmacies.[13]
References
[edit]- ^ ltd, Research and Markets. "Closed System Drug Transfer Devices - Research and Markets". www.researchandmarkets.com. Retrieved 2018-07-22.
- ^ Page, Michael (20 May 2016). "Closed-System Transfer Devices: Design Characteristics and Evolving Performance Standards". www.pharmacytimes.com. May 2016. 5 (3). Pharmacy & Healthcare Communications, LLC. Retrieved 15 May 2018.
- ^ "Equashield Named as Most Used Closed System in U.S. for Hazardous Drug Preparation and Administration for the Fourth Year Running". Yahoo. 15 November 2022. Retrieved 17 July 2023.
- ^ a b Hazani, Golan (6 October 2022). "Biotech company Equashield sells 25% stake to Nordic Capital at $1.3 billion valuation". Calcalist. Retrieved 17 July 2023.
- ^ Ruggles, Megan (12 September 2022). "Equashield's automated facility fulfills orders at 'record pace'". Supply Chain Dive. Retrieved 17 July 2023.
- ^ Cohen, Tova (17 April 2014). "Israeli sealed syringe maker Equashield sees surging sales". Reuters. Retrieved 17 July 2023.
- ^ "Equashield to Open New $30 Million Manufacturing Facility to Accommodate Future Growth in Product Portfolio and Increase Production Capabilities". MJH Life Sciences. 24 May 2017. Retrieved 17 July 2023.
- ^ Favier, Bertrand; Gilles, Laurence; Latour, Jean François; Desage, Michel; Giammarile, Francesco (March 2005). "Contamination of syringe plungers during the sampling of cyclophosphamide solutions". Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners. 11 (1): 1–5. doi:10.1191/1078155205jp147oa. ISSN 1078-1552.
- ^ Clark, Bernadette A.; Sessink, Paul J. M. (June 2013). "Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents". Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners. 19 (2): 99–104. doi:10.1177/1078155212468367. ISSN 1477-092X.
- ^ Smith, Stephen T.; Szlaczky, Mark C. (October 2014). "Syringe plunger contamination by hazardous drugs: a comparative study". Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners. 20 (5): 381–385. doi:10.1177/1078155214526428. ISSN 1477-092X.
- ^ Klein Leichman, Abigail (9 February 2014). "Equashield shields medical personnel from toxic drugs". ISRAEL21c. Retrieved 17 July 2023.
- ^ Shamah, David (12 January 2014). "Unique syringe keeps hospital staff safe from fatal drug residue". The Times of Israel. Retrieved 17 July 2023.
- ^ Ford, Omar (19 June 2018). "MDEA Winner Shows the Value of Nonsurgical Robots in Healthcare". Medical Device + Diagnostic Industry. Retrieved 17 July 2023.
External links
[edit]- EQUASHIELD in Facebook
- EQUASHIELDin Linkedin
- EQUASHIELD in YouTube
- EQUASHIELD in Twitter
- EQUASHIELD in Instagram
Category:Personal protective equipment Category:Occupational safety and health Category:Companies based in New York Category:Israeli companies established in 2009